VIVUS Appoints Kenneth Suh as President
August 06 2018 - 7:30AM
VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a
biopharmaceutical company, today announced the appointment of Ken
Suh to the position of President. Previously, Mr. Suh was
President and CEO of Willow Biopharma Inc., a wholly-owned
subsidiary of VIVUS, Inc. As President of VIVUS, Mr. Suh will work
to advance the Company toward its core objectives of product
portfolio optimization and enterprise value creation.
Mr. Suh founded Willow Biopharma Inc., a biopharmaceutical
company, in 2015 and served as President and Chief Executive
Officer. In April 2018, Willow Biopharma Inc. became a wholly-owned
subsidiary of VIVUS. Prior to establishing Willow, he founded KRIM
Biopharma Inc., where he served as President, Chief Executive
Officer and director. Before establishing KRIM, Mr. Suh held
multiple roles for Novartis Pharma Canada, including Franchise
Lead, Brand Manager, Associate Brand Manager and Medical
Representative. He received a Bachelor of Commerce, Honors Program
from the University of Guelph, Ontario.
“Ken has been instrumental in developing and executing our
corporate strategy since joining VIVUS in April, and his
appointment as President reflects the important contributions he
has already made toward advancing our key business objectives, most
notably, the recent acquisition of PANCREAZE,” said John Amos,
Chief Executive Officer at VIVUS. "Ken has a critical role to play
in helping us build a sustainable and profitable specialty
pharmaceutical company that creates value for patients and
investors."
About VIVUSVIVUS is a
biopharmaceutical company committed to the development and
commercialization of innovative therapies that focus on advancing
treatments for patients with serious unmet medical needs. For
more information about the Company, please
visit www.vivus.com.
Forward-Looking StatementsCertain statements in
this press release are forward-looking within the meaning of the
Private Securities Litigation Reform Act of 1995 and are subject to
risks, uncertainties and other factors, including risks and
uncertainties related to potential change in our business
strategy to enhance long-term stockholder value, including the
acquisition of revenue generating products and the strengthening of
our balance sheet; and risks and uncertainties related to the
impact, if any, of changes to our Board of Directors and senior
management team. These risks and uncertainties could
cause actual results to differ materially from those referred to in
these forward-looking statements. The reader is cautioned not
to rely on these forward-looking statements. Investors should read
the risk factors set forth in VIVUS’ Form 10-K for the year
ended December 31, 2017 as filed on March 14,
2018, and as amended by the Form 10-K/A filed on April
26, 2018,and periodic reports filed with the Securities and
Exchange Commission. VIVUS does not undertake an
obligation to update or revise any forward-looking statements.
CONTACT: |
|
|
|
|
|
|
|
|
|
VIVUS,
Inc. |
|
|
|
|
|
|
|
Investor
Relations |
Mark Oki |
|
|
|
|
|
|
|
Lazar
Partners |
Chief Financial
Officer |
|
|
|
|
|
|
|
David Carey |
oki@vivus.com |
|
|
|
|
|
|
|
dcarey@lazarpartners.com |
650-934-5200 |
|
|
|
|
|
|
|
212-687-1768 |
|
|
|
|
|
|
|
|
|
VIVUS (NASDAQ:VVUS)
Historical Stock Chart
From Mar 2024 to Apr 2024
VIVUS (NASDAQ:VVUS)
Historical Stock Chart
From Apr 2023 to Apr 2024